Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24386086)

1.

Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.

Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N, Fontana RJ, Watkins PB, Lee WM, Reddy KR, Stolz A, Talwalkar J, Davern T, Saha D, Bell LN, Barnhart H, Gu J, Serrano J, Bonkovsky HL.

PLoS One. 2013 Dec 27;8(12):e81974. doi: 10.1371/journal.pone.0081974. eCollection 2013.

2.

The potential of cytokines as safety biomarkers for drug-induced liver injury.

Laverty HG, Antoine DJ, Benson C, Chaponda M, Williams D, Kevin Park B.

Eur J Clin Pharmacol. 2010 Oct;66(10):961-76. doi: 10.1007/s00228-010-0862-x. Epub 2010 Aug 6. Review.

PMID:
20694460
3.

Comparative gene and protein expression analyses of a panel of cytokines in acute and chronic drug-induced liver injury in rats.

Hanafusa H, Morikawa Y, Uehara T, Kaneto M, Ono A, Yamada H, Ohno Y, Urushidani T.

Toxicology. 2014 Oct 3;324:43-54. doi: 10.1016/j.tox.2014.07.005. Epub 2014 Jul 19.

PMID:
25051504
4.

Role of immune reactions in drug-induced liver injury (DILI).

Ju C, Reilly T.

Drug Metab Rev. 2012 Feb;44(1):107-15. doi: 10.3109/03602532.2011.645579. Epub 2012 Jan 12. Review.

PMID:
22235834
5.

Serum proteomic profiling in patients with drug-induced liver injury.

Bell LN, Vuppalanchi R, Watkins PB, Bonkovsky HL, Serrano J, Fontana RJ, Wang M, Rochon J, Chalasani N; US Drug-Induced Liver Injury Network (DILIN) Research Group.

Aliment Pharmacol Ther. 2012 Mar;35(5):600-12.

6.

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J; United States Drug Induced Liver Injury Network.

Gastroenterology. 2015 Jun;148(7):1340-52.e7. doi: 10.1053/j.gastro.2015.03.006. Epub 2015 Mar 6.

PMID:
25754159
7.

Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA; DILIN Network.

Gastroenterology. 2014 Jul;147(1):96-108.e4. doi: 10.1053/j.gastro.2014.03.045. Epub 2014 Mar 27.

8.

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J; DILIN Study Group.

Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005.

9.

Clinical features, diagnosis, and natural history of drug-induced liver injury.

Hayashi PH, Fontana RJ.

Semin Liver Dis. 2014 May;34(2):134-44. doi: 10.1055/s-0034-1375955. Epub 2014 May 31. Review.

PMID:
24879979
10.

Antituberculous drug-induced liver injury: current perspective.

Devarbhavi H.

Trop Gastroenterol. 2011 Jul-Sep;32(3):167-74. Review.

11.

Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.

Xu HM, Chen Y, Xu J, Zhou Q.

World J Gastroenterol. 2012 Nov 7;18(41):5972-8. doi: 10.3748/wjg.v18.i41.5972.

12.

Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Fontana RJ.

Gastroenterology. 2014 Apr;146(4):914-28. doi: 10.1053/j.gastro.2013.12.032. Epub 2013 Dec 31. Review.

13.

Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury.

Lai R, Xiang X, Mo R, Bao R, Wang P, Guo S, Zhao G, Gui H, Wang H, Bao S, Xie Q.

J Hepatol. 2015 Jul;63(1):148-55. doi: 10.1016/j.jhep.2015.02.004. Epub 2015 Feb 12.

PMID:
25681556
14.

Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome.

Pachkoria K, Lucena MI, Crespo E, Ruiz-Cabello F, Lopez-Ortega S, Fernandez MA, Romero-Gomez M, Madrazo A, Durán JA, de Dios AM, Borraz Y, Navarro JM, Andrade RJ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)).

J Hepatol. 2008 Jul;49(1):107-14. doi: 10.1016/j.jhep.2008.03.017. Epub 2008 Apr 22. Erratum in: J Hepatol. 2009 Mar;50(3):636.

PMID:
18485518
15.

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network.

Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. Review.

16.

Th2 cytokine-mediated methimazole-induced acute liver injury in mice.

Kobayashi M, Higuchi S, Ide M, Nishikawa S, Fukami T, Nakajima M, Yokoi T.

J Appl Toxicol. 2012 Oct;32(10):823-33. doi: 10.1002/jat.2731. Epub 2012 Mar 9.

PMID:
22407903
17.

Immunoallergic drug-induced liver injury in humans.

Uetrecht J.

Semin Liver Dis. 2009 Nov;29(4):383-92. doi: 10.1055/s-0029-1240007. Epub 2009 Oct 13. Review.

PMID:
19826972
18.

Drug-induced liver injury.

Leise MD, Poterucha JJ, Talwalkar JA.

Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016. Review.

PMID:
24388027
19.

Mechanisms of drug-induced liver injury.

Holt MP, Ju C.

AAPS J. 2006 Feb 3;8(1):E48-54. Review.

20.

An update on drug induced liver injury.

Rangnekar AS, Fontana RJ.

Minerva Gastroenterol Dietol. 2011 Jun;57(2):213-29. Review.

PMID:
21587150
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk